Mereo Historical Cash Flow
| MREO Stock | USD 3.56 0.16 4.71% |
Analysis of Mereo BioPharma cash flow over time is an excellent tool to project Mereo BioPharma Group future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Exchange Rate Changes of 0.0 or Depreciation of 699.6 K as it is a great indicator of Mereo BioPharma ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Mereo BioPharma Group latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Mereo BioPharma Group is a good buy for the upcoming year.
Mereo |
About Mereo Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Mereo balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Mereo's non-liquid assets can be easily converted into cash.
Mereo BioPharma Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Mereo BioPharma Group to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Mereo BioPharma operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Mereo BioPharma's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Mereo BioPharma Group current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. At this time, Mereo BioPharma's Change To Account Receivables is very stable compared to the past year. As of the 29th of November 2024, Change To Liabilities is likely to grow to about 1.1 M, while Investments are likely to drop (439.9 K).
Mereo BioPharma cash flow statement Correlations
Click cells to compare fundamentals
Mereo BioPharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Mereo BioPharma cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | 43.3M | 1.5M | (421K) | 1.5M | (419K) | (440.0K) | |
| Change In Cash | (8.7M) | 7.1M | 70.8M | (38.0M) | (10.8M) | (10.2M) | |
| Net Borrowings | (2.2M) | 22.5M | (692K) | (937K) | (843.3K) | (801.1K) | |
| Total Cashflows From Investing Activities | 252K | 43.3M | 1.5M | (421K) | (484.2K) | (459.9K) | |
| Other Cashflows From Financing Activities | (2.5M) | (23.4M) | (253.7K) | 350.0K | (444K) | (466.2K) | |
| Depreciation | 1.6M | 1.6M | 642K | 727K | 1.1M | 699.6K | |
| Capital Expenditures | 21K | 16K | 535K | 10K | 419K | 315.7K | |
| Total Cash From Operating Activities | (45.9M) | (28.3M) | (5.2M) | (38.8M) | (21.1M) | (22.2M) | |
| Change To Account Receivables | (936K) | 141K | (589K) | 695K | 456K | 478.8K | |
| Net Income | (41.1M) | (166.5M) | 14.2M | (36.1M) | (29.5M) | (30.9M) | |
| Total Cash From Financing Activities | (5.7M) | 34.7M | 77.7M | (784K) | 8.0M | 7.6M | |
| End Period Cash Flow | 16.3M | 23.5M | 94.3M | 56.3M | 57.4M | 47.5M | |
| Other Cashflows From Investing Activities | 286K | 377K | 44K | 1K | 900.0 | 855.0 | |
| Change To Netincome | 6.4M | (5.0M) | 137.1M | (16.8M) | (19.3M) | (18.3M) | |
| Change To Liabilities | (6.7M) | (3.6M) | (1.3M) | 1.1M | 1.0M | 1.1M | |
| Stock Based Compensation | 1.6M | 2.1M | 4.5M | 4.8M | 4.9M | 4.2M | |
| Free Cash Flow | (46.0M) | (28.4M) | (5.8M) | (38.8M) | (21.6M) | (22.6M) | |
| Change In Working Capital | (7.7M) | (3.4M) | (1.8M) | 1.8M | (1.6M) | (1.7M) | |
| Begin Period Cash Flow | 25.0M | 16.3M | 23.5M | 94.3M | 68.2M | 47.2M | |
| Other Non Cash Items | (429K) | 5.2M | 13.4M | (9.1M) | 3.9M | 2.2M |
Pair Trading with Mereo BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Mereo Stock
| 0.67 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.65 | VTRS | Viatris | PairCorr |
| 0.54 | ESPR | Esperion Therapeutics | PairCorr |
| 0.52 | GILD | Gilead Sciences | PairCorr |
| 0.47 | BFRIW | Biofrontera Warrants | PairCorr |
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.